



Performance Enhanced Pharmaceuticals providing fast relief when it's needed most


EquiTech Corporation  
TSXV: "EQT"

## Technology Fact Sheet


EquiTech is a specialty pharmaceutical company developing better absorbing versions of existing oral medications. Using our Enhanced Absorption Technology platform we have developed our lead compound, ZAG-1701, which is a faster absorbing ibuprofen caplet for acute pain relief. ZAG-1701 is the first Performance Enhanced Pharmaceutical product from our development pipeline ready to begin Phase II clinical trials.

### Enhanced Absorption Technology

- EQT founder and CSO Dr. F. Jamali discovered that **people in pain absorb ibuprofen slower**, compared to healthy patients (1999)
- EQT developed technology platform to **enhance the absorption of drugs** that works even when the patient is in pain or when stomach activity is reduced
- **Lead compound ZAG-1701 is an ibuprofen tablet** that absorbs faster than standard ibuprofen (see graph)
- **COX-2 inhibitor** enhanced absorbing formulation developed using proprietary pain mimicking animal model
- **Proprietary animal model** mimics the reduced stomach activity that occurs in response to acute pain and is also characteristic of the geriatric patient



ZAG-1701 absorbs faster than standard ibuprofen in pain-mimicking animal model



### Shorter Time to Market

- ZAG-1701 - A Phase II proof-of-concept clinical trial will be done to demonstrate **more rapid pain relief** vs. another ibuprofen product on the market. Trial is expected to **take 2 to 3 months**
- ZAG-1701 - GMP manufacture of clinical trial quantities is complete
- Use of already approved pharmaceuticals **minimizes risk and time needed for clinical trials**
- U.S. and international **patents pending** on lead compounds and innovative research tools to develop new formulations

### A Pipeline of Products

- 3 enhanced **pain relief products**
  - ZAG-1701 ibuprofen - Phase II clinical trials
  - COX-2 inhibitor - late stage pre-clinical
  - Naproxen - late stage pre-clinical
- **Additional products** based on Enhanced Absorption Technology will be developed for other conditions where fast relief is needed or where stomach function is reduced

### Strength in Partners

- Manufacturing partner **Patheon** and regulatory consultant **CanReg** are among the best in the business
- Equity partner **Ethypharm** has cGMP manufacturing capability
- Major **distribution/marketing partner** will be sought after clinical trials for each EQT product

### Key Contact

**James Chivers-Wilson**  
President & Chief Executive Officer  
Tel: 780.430.1633 Fax: 780.430.1355  
james@equitechcorporation.com

**EquiTech Corporation**  
Suite 3048, 8308 114th Street  
Edmonton, Alberta, Canada T6G 2E1  
<http://www.equitechcorporation.com>

*This document may contain forward-looking statements, i.e. information that is not strictly historical, concerning EquiTech's business and prospects. Forward-looking statements are subject to a number of risks and uncertainties. Actual events and results may differ materially from those discussed in this document, due to factors including research, development, commercial and market risks.*